IperionX (NASDAQ: IPX) responds to ASX share price query and confirms compliance
Rhea-AI Filing Summary
IperionX Limited filed a Form 6-K mainly to publish correspondence with the Australian Securities Exchange after a sharp share price move. ASX queried a change in IPX’s price from a high of $6.93 on 12 March 2026 to an intraday low of $4.58 on 16 March 2026. IperionX stated it is not aware of any information or reason that would explain the trading pattern, other than previously released disclosures. The company highlighted that its half year report was released last week and noted stakeholder questions about the funding mechanics of its U.S. Department of War grants. IperionX also confirmed it remains in compliance with ASX Listing Rules, including continuous disclosure obligations.
Positive
- None.
Negative
- None.
Insights
IperionX says it has no undisclosed information explaining the recent share price drop and confirms compliance with disclosure rules.
The correspondence shows IperionX responding to an ASX query after its share price fell from $6.93 to an intraday low of $4.58 over several days. The company explicitly states it is not aware of any specific information that would account for this trading behavior.
IperionX references its recently released half year report and notes investor interest in the funding mechanics of its U.S. Department of War grants, but does not link these directly to the price move. It also confirms compliance with ASX Listing Rule 3.1 on continuous disclosure, indicating no additional material information has been withheld based on the statements provided here.
|
Exhibit
|
Description
|
|
|
99.1
|
ASX Correspondence
|
|
|
IPERIONX LIMITED
|
|||
|
(registrant)
|
|||
|
Date: March 16, 2026
|
By:
|
/s/ Marcela Castro |
|
|
Name:
|
Marcela Castro | |
|
Title:
|
Chief Financial Officer |
 |
March 16, 2026
|
|
1.
|
Is IPX aware of any information concerning it that has not been announced to the market which, if known by some in the market,
could explain the recent trading in its securities?
|
|
2.
|
If the answer to question 1 is “yes”
|
|
3.
|
If the answer to question 1 is “no”, is there any other explanation that IPX may have for the recent trading in its securities?
|
|
1.
|
IperionX makes cash payments for spending upon projects under its U.S. Department of War grants.
|
|
2.
|
The U.S. Government subsequently re-imburses IperionX after these payments have been made.
|
|
3.
|
For the period to Dec 31, 2025, approximately $6.6 million in payments were incurred that were not yet reimbursed.
|
|
4.
|
Under IperionX’s accounting treatment, the Company procures equipment solely in an agency capacity on behalf of the U.S. Government. When an asset is
purchased for the U.S. Government, IperionX records a receivable representing the amount due for reimbursement, rather than recognizing the asset or related expense.
|
|
5.
|
The U.S. Government can elect to, but is not obliged to, transfer title to all or a portion of equipment or real property to IperionX at the
conclusion of the U.S. Department of War projects.
|
|
6.
|
As previously disclosed in the December 31, 2025 quarterly activities report, a balance of $46.5 million remains available for reimbursement from the
U.S. Government.
|
|
4.
|
Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1
|
|
5.
|
Approval of responses
|
|
|
Virginia
|
Tennessee
|
Utah
|
|
1092 Confroy Drive
South Boston, VA 24592
|
279 West Main Street
Camden, TN 38320
|
1782 W 2300 S
West Valley City, UT 84119
|
|
|
IperionX Limited ABN 84 618 935 372
|
|||